This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 103/8/813    most recent CIRCRESAHA.108.179754v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marin, T. M. Articles by Franchini, K. G. Search for Related Content PubMed PubMed Citation Articles by Marin, T. M. Articles by Franchini, K. G. Related Collections Other myocardial biology Hypertrophy Physiological and pathological control of gene expression Related Article

(Circulation Research. 2008;103:813.)
© 2008 American Heart Association, Inc.

Molecular Medicine

Shp2 Negatively Regulates Growth in Cardiomyocytes by Controlling Focal Adhesion Kinase/Src and mTOR Pathways

Talita M. Marin, Carolina F.M.Z. Clemente, Aline M. Santos, Paty K. Picardi, Vinícius D.B. Pascoal, Iscia Lopes-Cendes, Mário J.A. Saad, Kleber G. Franchini

From the Department of Internal Medicine (T.M.M., C.F.M.Z.C., A.M.S., P.K.P., M.J.A.S., K.G.F.) and Department of Medical Genetics (V.D.B.P., I.L.-C.), Faculty of Medical Sciences, State University of Campinas, Sao Paulo, Brazil.

Correspondence to Kleber G. Franchini, MD, PhD, Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas (UNICAMP), Cidade Universitária "Zeferino Vaz", 13081-970, Campinas, Sao Paulo, Brazil. E-mail franchin{at}unicamp.br

The aim of this study was to investigate whether Shp2 (Src homology region 2, phosphatase 2) controls focal adhesion kinase (FAK) activity and its trophic actions in cardiomyocytes. We show that low phosphorylation levels of FAK in nonstretched neonatal rat ventricular myocytes (NRVMs) coincided with a relatively high basal association of FAK with Shp2 and Shp2 phosphatase activity. Cyclic stretch (15% above initial length) enhanced FAK phosphorylation at Tyr397 and reduced FAK/Shp2 association and phosphatase activity in anti-Shp2 precipitates. Recombinant Shp2 C-terminal protein tyrosine phosphatase domain (Shp2-PTP) interacted with nonphosphorylated recombinant FAK and dephosphorylated FAK immunoprecipitated from NRVMs. Depletion of Shp2 by specific small interfering RNA increased the phosphorylation of FAK Tyr397, Src Tyr418, AKT Ser473, TSC2 Thr1462, and S6 kinase Thr389 and induced hypertrophy of nonstretched NRVMs. Inhibition of FAK/Src activity by PP2 {4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine} abolished the phosphorylation of AKT, TSC2, and S6 kinase, as well as the hypertrophy of NRVMs induced by Shp2 depletion. Inhibition of mTOR (mammalian target of rapamycin) with rapamycin blunted the hypertrophy in NRVMs depleted of Shp2. NRVMs treated with PP2 or depleted of FAK by specific small interfering RNA were defective in FAK, Src, extracellular signal-regulated kinase, AKT, TSC2, and S6 kinase phosphorylation, as well as in the hypertrophic response to prolonged stretch. The stretch-induced hypertrophy of NRVMs was also prevented by rapamycin. These findings demonstrate that basal Shp2 tyrosine phosphatase activity controls the size of cardiomyocytes by downregulating a pathway that involves FAK/Src and mTOR signaling pathways.

Key Words: hypertrophy • cell signaling • cardiomyocytes • focal adhesion kinase

Related Article:

Shp Shape: FAKs About Hypertrophy

Kathleen A. Martin and John Hwa
Circ. Res. 2008 103: 776-778. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				K. A. Martin and J. Hwa Shp Shape: FAKs About Hypertrophy Circ. Res., October 10, 2008; 103(8): 776 - 778. [Full Text] [PDF]